The FDA has approved clesrovimab, marketed as Enflonsia, for the prevention of RSV lower respiratory tract disease in ...

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent ...